CO2023013791A2 - Inhibidores terapéuticos de la señalización de gdf15 - Google Patents

Inhibidores terapéuticos de la señalización de gdf15

Info

Publication number
CO2023013791A2
CO2023013791A2 CONC2023/0013791A CO2023013791A CO2023013791A2 CO 2023013791 A2 CO2023013791 A2 CO 2023013791A2 CO 2023013791 A CO2023013791 A CO 2023013791A CO 2023013791 A2 CO2023013791 A2 CO 2023013791A2
Authority
CO
Colombia
Prior art keywords
gdf15
gfral
relates
therapeutic inhibitors
gdf15 signaling
Prior art date
Application number
CONC2023/0013791A
Other languages
English (en)
Inventor
E-Chiang Lee
Hui Liu
Adam Carpenter
Stephen O’Rahilly
Anthony Patrick Coll
Irene Cimino
Original Assignee
Kymab Ltd
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104556.2A external-priority patent/GB202104556D0/en
Priority claimed from GBGB2107331.7A external-priority patent/GB202107331D0/en
Priority claimed from GBGB2108170.8A external-priority patent/GB202108170D0/en
Application filed by Kymab Ltd, Cambridge Entpr Ltd filed Critical Kymab Ltd
Publication of CO2023013791A2 publication Critical patent/CO2023013791A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Esta invención se refiere a anticuerpos que se unen a e inhiben la actividad de la proteína receptora similar a alfa de la familia del factor neurotrófico derivado de las células gliales (GFRAL). La invención también se refiere a la ruta de señalización GDF15-GFRAL como una diana terapéutica para estados de caquexia y afecciones que implican una reducción de la toma de alimentos y reducción en la masa muscular y grasa
CONC2023/0013791A 2021-03-31 2023-10-19 Inhibidores terapéuticos de la señalización de gdf15 CO2023013791A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2104556.2A GB202104556D0 (en) 2021-03-31 2021-03-31 Therapeutic inhibitors of GDF15 signalling
GBGB2107331.7A GB202107331D0 (en) 2021-05-21 2021-05-21 Therapeutic inhibitors of GDF15 signalling
GBGB2108170.8A GB202108170D0 (en) 2021-06-08 2021-06-08 Theraputic inhibitors of GDF15 Signalling
PCT/EP2022/058669 WO2022207846A1 (en) 2021-03-31 2022-03-31 Therapeutic inhibitors of gdf15 signalling

Publications (1)

Publication Number Publication Date
CO2023013791A2 true CO2023013791A2 (es) 2024-01-25

Family

ID=81580347

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0013791A CO2023013791A2 (es) 2021-03-31 2023-10-19 Inhibidores terapéuticos de la señalización de gdf15

Country Status (9)

Country Link
EP (1) EP4314071A1 (es)
JP (1) JP2024511853A (es)
KR (1) KR20230165285A (es)
AU (1) AU2022251923A1 (es)
BR (1) BR112023020152A2 (es)
CA (1) CA3215737A1 (es)
CO (1) CO2023013791A2 (es)
IL (1) IL307382A (es)
WO (1) WO2022207846A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
BR112012014022A2 (pt) 2009-12-11 2017-04-04 Genecode As composto, composição, dispositivo médico e método ex vivo para modulação do crescimento de um neurônico
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
HUE044363T2 (hu) 2012-09-26 2019-10-28 Univ Wuerzburg J Maximilians Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek
AU2013364133B2 (en) 2012-12-21 2018-10-11 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies
PT3122775T (pt) 2014-03-26 2019-12-26 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
EP3197493B1 (en) 2014-09-25 2021-03-10 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
CN108463246A (zh) 2015-10-02 2018-08-28 尤利乌斯·马克西米利安维尔茨堡大学 使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
WO2017147742A1 (en) 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
AU2017228489A1 (en) 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
IL261666B1 (en) 2016-03-31 2024-05-01 Ngm Biopharmaceuticals Inc Related proteins and methods of using them
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用

Also Published As

Publication number Publication date
EP4314071A1 (en) 2024-02-07
AU2022251923A1 (en) 2023-11-16
JP2024511853A (ja) 2024-03-15
BR112023020152A2 (pt) 2023-11-14
CA3215737A1 (en) 2022-10-06
WO2022207846A1 (en) 2022-10-06
KR20230165285A (ko) 2023-12-05
IL307382A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA202092605A1 (ru) Антитела к ил-11ra
EA201370081A1 (ru) Антитела к cd48 и их применение
BR112012033422B8 (pt) formulação de alimentação por sonda de alimentação diária completa, seu uso e seu método de fabricação
CO7240399A2 (es) Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos
AR058983A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
CL2017001237A1 (es) Métodos y composiciones para conservar la masa corporal magra y promover la pérdida de grasa durante la pérdida de peso.
UY30468A1 (es) Compuestos quimicos.
EA201290589A1 (ru) Cd127-связывающие белки
CO2023013791A2 (es) Inhibidores terapéuticos de la señalización de gdf15
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
DOP2022000229A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
EA201691436A1 (ru) Композиция, включающая окру для применения в уменьшении абсорбции пищевого жира
AR127513A2 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
EA202091226A1 (ru) Применение лигниновой фракции в качестве ингредиента пищевой добавки для человека и животных
MX2020004397A (es) Uso de suplementos de aminoacidos para mejorar la sintesis de proteinas musculares.
EP4143322A4 (en) MISFOLDED TDP-43 SINGLE CHAIN ANTIBODIES AND INTRABODY AND METHOD OF USE
BR112014000198A2 (pt) composição com uma textura semelhante a iogurte
BR112022019930A2 (pt) Dieta para colite ulcerativa, fórmulas, produtos e métodos dos mesmos
GB2564295A (en) Chromium containing compositions for improving health and fitness
BR112013020913A2 (pt) tratamento de doença de crohn fistulizante
MX2023000949A (es) Anticuerpos anti-beta-amiloide (abeta).
EA202190504A1 (ru) Способы лечения псориаза
CO2023000852A2 (es) Proteína de unión a antígeno